[{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"RNA Therapeutic","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Therapeutics \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"siRNA Therapeutic","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Rona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rona Therapeutics \/ Rona Therapeutics"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rona Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"14","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"}]

Find Clinical Drug Pipeline Developments & Deals by Rona Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of the company's first program RN0191, a best-in-class PCSK9 siRNA program, which is being evaluated for treating Hypercholesteremia.

                          Brand Name : RN0191

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 19, 2024

                          Lead Product(s) : RN0191

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : LongRiver Investments

                          Deal Size : $35.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Rona licensed Sanofi’s siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neuro and muscular disease candidates for ex-China territories.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 25, 2022

                          Lead Product(s) : siRNA Therapeutic

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Preclinical

                          Recipient : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 07, 2022

                          Lead Product(s) : RNA Therapeutic

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Lilly Asia Ventures

                          Deal Size : $33.0 million

                          Deal Type : Series A Financing

                          blank